Advanced Filters
noise

Falls Church, Virginia Clinical Trials

A listing of Falls Church, Virginia clinical trials actively recruiting patient volunteers.

Found 1,850 clinical trials
M Mark S Nash, PhD

Spinal Cord Injury Model Systems (SCIMS) - Education Module

The purpose of this study is to find out if receiving education regarding increased risks of cardiometabolic disease helps subjects understand these risks and how these risks participants' health.

18 - 70 years of age All Phase N/A
B Bhaumik Patel, MD

Repositioning Immunotherapy in VetArans With Lung Cancer

This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC.

18 years of age All Phase 2
T Toby L Perkins

Microbiome Population Adaptation Study

The investigators will accomplish our research aims by collecting cutaneous microbiome samples from 50 persons that have undergone the Osseointegration (OI) surgery at eight timepoints, prospectively. The investigators will also collect control samples to correct for turnovers in species compositions that may naturally occur and to compare the residual limb …

18 - 75 years of age All Phase N/A
E Erica Torres

PAS-004 in Patients With Advanced Solid Tumors

The main purpose of this clinical trial is to test PAS-004 in people with advanced solid tumors with rat sarcoma virus (RAS), neurofibromatosis type I (NF1), or rapidly accelerated fibrosarcoma (RAF) mutations. The main questions it aims to answer are: How well participants are able tolerate different doses of PAS-004, …

18 years of age All Phase 1
F For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)

Ultra-Low Field (ULF) Point-of-Care (POC) MRI System for Brain Morphology and Pathology

Background Magnetic resonance imaging (MRI) is a tool for getting pictures of the tissues and organs inside the body. MRI can help diagnose many injuries and diseases. But not all patients are equally likely to receive MRIs. Factors such as race or ethnicity, distance to imaging centers, mobility, and a …

3 - 99 years of age All Phase N/A
U US GSK Clinical Trials Call Center

Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics

The purpose of this study is to provide data on the pharmacokinetic (PK), safety, tolerability, efficacy and acceptability of this fixed dose combination (FDC) single tablet 2-drug regimen for virologically suppressed (HIV-1 RNA \[Ribonucleic Acid\] \< 50 \[cells per milliliter\] c/mL) children 6 to less than 12 years of age, …

6 - 12 years of age All Phase 1/2
M Maryanne Odinakachukwu

Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody

This multicenter prospective study seeks to determine if daratumumab given, prior to HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus, can prevent pure red blood cell aplasia with an acceptable safety profile in patients with anti-donor red blood cell antibodies, achieving an event-free survival similar to …

2 - 25 years of age All Phase 2
F For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

Background Cisplatin is used to treat head and neck cancer. People who take this drug are at risk for hearing loss. Atorvastatin is a drug used to treat high cholesterol. It might reduce the risk of cisplatin-induced hearing loss. Objective To find out if atorvastatin reduces hearing loss in people …

18 - 100 years of age All Phase 2
F For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)

Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study

Background Hemophagocytic lymphohistiocytosis (HLH) is a disease caused by disrupted immune function. People with HLH are prone to fevers and illnesses, which can be fatal. Some people develop a genetic form of this disease (pHLH), but researchers do not understand why some other people develop a nongenetic form (sHLH). They …

18 - 120 years of age All Phase N/A
L Lisa Ley

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

Background Small cell carcinoma of the bladder (SCCB) and other high-grade neuroendocrine tumors (HGNET) of the urinary tract are rare but aggressive cancers. Average survival for people diagnosed with SCCB or HGNET is about 1 year. Lurbinectedin and avelumab are drugs that are approved to treat other cancers. Researchers want …

18 - 120 years of age All Phase 2

Simplify language using AI